Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritlecitinib in Pediatric Participants With Severe Alopecia Areata
NCT07029711Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of ritlecitinib tosilate in alopecia areata (3 arms), sponsored by Pfizer. Primary endpoints: Severity of Alopecia Tool score <=20 at 24 weeks and Severity of Alopecia Tool score <=10 at 24 weeks. Started Jul 2025; status: active, not recruiting.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT07029711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07029711.